Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,changeToLiabilities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,changeToInventory,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Feb 27, 2019) 4","Short Ratio (Feb 27, 2019) 4","Short % of Float (Feb 27, 2019) 4","Short % of Shares Outstanding (Feb 27, 2019) 4","Shares Short (prior month Jan 30, 2019) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,IPCIF,-7188665,33092700,547485,,-924566,,-924566,206755,0,-819622,-819622,,-75600,,,,0,0,819622,0,-104944,,-924566,-924566,2727,44406355,9868973,-7185938,38511,2683035,46144402,-98021116,284421,202669,9868973,284421,1804716,875592,482135,112672,4250690,221267.0,-707.0,623.0,623.0,64992.0,566384.0,72863.0,,,,-8993381,en-US,US,EQUITY,False,Delayed Quote,11114,0.092999995,1.55,0.06 - 0.48,-0.327,-0.68125,0.06,0.48,1536883200,-0.303,0.16371429,-0.0107142925,-0.065445065,0.19818841,-0.045188412,5063183,4,0.9567814,-0.50495046,15,America/New_York,EDT,-14400000,0.153 - 0.153,0.15155,0.0,0.0,0,0,finmb_23127248,Other OTC,Intellipharmaceutics International Inc.,USD,9603,USD,False,False,0.153,1630509167,0.0014500022,0.153,0.153,0.153,500,PNK,INTELLIPHARMACEUTICS INTL INC,0,us_market,PRE,-0.108,-0.22800735,1.15,,,0.48,0.06,0.1637,0.1982,9.6k,11.11k,33.09M,,21.37M,1.76%,11.27%,714k,0.39,3.35%,3.26%,211.76k,,,,,,0.00%,"Sep 13, 2018",,1:10,"Sep 13, 2018","Nov 29, 2020","Feb 27, 2021",-250.81%,-420.10%,-85.53%,,1.02M,0.04,,1.4M,-3.93M,-2.57M,-0.1080,,202.67k,0.01,2.06M,,0.09,-0.30,171.3k,-555.4k,Value,M9W 5X2,Healthcare,13,"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",Toronto,416 798 3001,ON,1609372800,Canada,http://www.intellipharmaceutics.com,86400,30 Worcester Road,416 798 3007,Biotechnology
t-1,IPCIF,-6316706,33092700,1091001,,-1589267,,-1622100,562848,299442,-1462406,-1462406,,-82318,,,,32833,299442,1761848,0,-126861,,-1622100,-1622100,3117,44354138,9700644,-6313589,638511,3387055,46144402,-97096550,284421,202046,9700644,284421,1904951,1478987,1048519,112672,4103966,473520.0,-49681.0,-596510.0,-616895.0,107220.0,-42501.0,585410.0,20385.0,-102375.0,,-8221657,en-US,US,EQUITY,False,Delayed Quote,11114,0.092999995,1.55,0.06 - 0.48,-0.327,-0.68125,0.06,0.48,1536883200,-0.303,0.16371429,-0.0107142925,-0.065445065,0.19818841,-0.045188412,5063183,4,0.9567814,-0.50495046,15,America/New_York,EDT,-14400000,0.153 - 0.153,0.15155,0.0,0.0,0,0,finmb_23127248,Other OTC,Intellipharmaceutics International Inc.,USD,9603,USD,False,False,0.153,1630509167,0.0014500022,0.153,0.153,0.153,500,PNK,INTELLIPHARMACEUTICS INTL INC,0,us_market,PRE,-0.108,-0.22800735,1.15,,,0.48,0.06,0.1637,0.1982,9.6k,11.11k,33.09M,,21.37M,1.76%,11.27%,714k,0.39,3.35%,3.26%,211.76k,,,,,,0.00%,"Sep 13, 2018",,1:10,"Sep 13, 2018","Nov 29, 2020","Feb 27, 2021",-250.81%,-420.10%,-85.53%,,1.02M,0.04,,1.4M,-3.93M,-2.57M,-0.1080,,202.67k,0.01,2.06M,,0.09,-0.30,171.3k,-555.4k,Value,M9W 5X2,Healthcare,13,"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",Toronto,416 798 3001,ON,1609372800,Canada,http://www.intellipharmaceutics.com,86400,30 Worcester Road,416 798 3007,Biotechnology
t-2,IPCIF,-4688165,33092700,842846,,1026941,,1026941,513121,328781,-1129440,-1129440,,-133137,,,,0,328781,1458221,0,2156381,,1026941,1026941,3896,44361358,8901540,-4684269,5678,4217271,46144402,-95474450,284421,798556,8901540,284421,1903990,2309385,1159518,246756,4069023,-334655.0,87411.0,726458.0,721527.0,102254.0,-283204.0,122780.0,4931.0,-102375.0,-3875.0,-6592155,en-US,US,EQUITY,False,Delayed Quote,11114,0.092999995,1.55,0.06 - 0.48,-0.327,-0.68125,0.06,0.48,1536883200,-0.303,0.16371429,-0.0107142925,-0.065445065,0.19818841,-0.045188412,5063183,4,0.9567814,-0.50495046,15,America/New_York,EDT,-14400000,0.153 - 0.153,0.15155,0.0,0.0,0,0,finmb_23127248,Other OTC,Intellipharmaceutics International Inc.,USD,9603,USD,False,False,0.153,1630509167,0.0014500022,0.153,0.153,0.153,500,PNK,INTELLIPHARMACEUTICS INTL INC,0,us_market,PRE,-0.108,-0.22800735,1.15,,,0.48,0.06,0.1637,0.1982,9.6k,11.11k,33.09M,,21.37M,1.76%,11.27%,714k,0.39,3.35%,3.26%,211.76k,,,,,,0.00%,"Sep 13, 2018",,1:10,"Sep 13, 2018","Nov 29, 2020","Feb 27, 2021",-250.81%,-420.10%,-85.53%,,1.02M,0.04,,1.4M,-3.93M,-2.57M,-0.1080,,202.67k,0.01,2.06M,,0.09,-0.30,171.3k,-555.4k,Value,M9W 5X2,Healthcare,13,"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",Toronto,416 798 3001,ON,1609372800,Canada,http://www.intellipharmaceutics.com,86400,30 Worcester Road,416 798 3007,Biotechnology
t-3,IPCIF,-5812102,33092700,635326,,-1048433,,-1048433,548232,395740,-890241,-890241,,-180258,,,,0,395740,1285981,0,-158192,,-1048433,-1048433,4675,44265141,9370677,-5807427,5678,3563250,46144402,-96501391,284421,72098,9370677,284421,2031340,1527235,1016415,246756,4296577,874001.0,87411.0,66046.0,66046.0,102423.0,23558.0,134151.0,4931.0,-19654.0,-3875.0,-7843442,en-US,US,EQUITY,False,Delayed Quote,11114,0.092999995,1.55,0.06 - 0.48,-0.327,-0.68125,0.06,0.48,1536883200,-0.303,0.16371429,-0.0107142925,-0.065445065,0.19818841,-0.045188412,5063183,4,0.9567814,-0.50495046,15,America/New_York,EDT,-14400000,0.153 - 0.153,0.15155,0.0,0.0,0,0,finmb_23127248,Other OTC,Intellipharmaceutics International Inc.,USD,9603,USD,False,False,0.153,1630509167,0.0014500022,0.153,0.153,0.153,500,PNK,INTELLIPHARMACEUTICS INTL INC,0,us_market,PRE,-0.108,-0.22800735,1.15,,,0.48,0.06,0.1637,0.1982,9.6k,11.11k,33.09M,,21.37M,1.76%,11.27%,714k,0.39,3.35%,3.26%,211.76k,,,,,,0.00%,"Sep 13, 2018",,1:10,"Sep 13, 2018","Nov 29, 2020","Feb 27, 2021",-250.81%,-420.10%,-85.53%,,1.02M,0.04,,1.4M,-3.93M,-2.57M,-0.1080,,202.67k,0.01,2.06M,,0.09,-0.30,171.3k,-555.4k,Value,M9W 5X2,Healthcare,13,"Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",Toronto,416 798 3001,ON,1609372800,Canada,http://www.intellipharmaceutics.com,86400,30 Worcester Road,416 798 3007,Biotechnology
